vs
博士伦健康（BHC）与欧加隆（OGN）财务数据对比。点击上方公司名可切换其他公司
博士伦健康的季度营收约是欧加隆的1.9倍（$2.8B vs $1.5B），博士伦健康净利率更高（-3.7% vs -13.6%，领先9.9%），博士伦健康同比增速更快（9.3% vs -5.3%），博士伦健康自由现金流更多（$403.0M vs $96.0M），过去两年博士伦健康的营收复合增速更高（14.0% vs -3.6%）
博士伦健康公司（Bausch Health）是一家业务多元化的北美跨国制药企业，全球总部位于加拿大魁北克省拉瓦尔，美国总部设在新泽西州布里奇沃特。公司专注于胃肠病、肝病、神经科、皮肤科、牙科、医疗美容等领域的药物研发、生产及销售，同时提供品牌药和仿制药产品，业务覆盖全球市场。
欧加隆是一家总部位于美国新泽西州泽西城的制药企业，核心业务覆盖生殖医学、避孕、精神科、激素替代疗法及麻醉领域的药物研发与生产。公司所有产品均在美国境外生产，同时美国市场贡献了其三分之一的营收。
BHC vs OGN — 直观对比
营收规模更大
BHC
是对方的1.9倍
$1.5B
营收增速更快
BHC
高出14.6%
-5.3%
净利率更高
BHC
高出9.9%
-13.6%
自由现金流更多
BHC
多$307.0M
$96.0M
两年增速更快
BHC
近两年复合增速
-3.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $2.8B | $1.5B |
| 净利润 | $-103.0M | $-205.0M |
| 毛利率 | — | 49.2% |
| 营业利润率 | 17.0% | -9.8% |
| 净利率 | -3.7% | -13.6% |
| 营收同比 | 9.3% | -5.3% |
| 净利润同比 | -205.1% | -288.1% |
| 每股收益（稀释后） | $-0.30 | $-0.78 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BHCOGN
| Q4 25 | $2.8B | $1.5B | ||
| Q3 25 | $2.7B | $1.6B | ||
| Q2 25 | $2.5B | $1.6B | ||
| Q1 25 | $2.3B | $1.5B | ||
| Q4 24 | $2.6B | $1.6B | ||
| Q3 24 | $2.5B | $1.6B | ||
| Q2 24 | $2.4B | $1.6B | ||
| Q1 24 | $2.2B | $1.6B |
净利润BHCOGN
| Q4 25 | $-103.0M | $-205.0M | ||
| Q3 25 | $179.0M | $160.0M | ||
| Q2 25 | $148.0M | $145.0M | ||
| Q1 25 | $-58.0M | $87.0M | ||
| Q4 24 | $98.0M | $109.0M | ||
| Q3 24 | $-85.0M | $359.0M | ||
| Q2 24 | $10.0M | $195.0M | ||
| Q1 24 | $-64.0M | $201.0M |
毛利率BHCOGN
| Q4 25 | — | 49.2% | ||
| Q3 25 | — | 53.5% | ||
| Q2 25 | — | 54.8% | ||
| Q1 25 | — | 55.6% | ||
| Q4 24 | — | 56.3% | ||
| Q3 24 | — | 58.3% | ||
| Q2 24 | — | 58.4% | ||
| Q1 24 | — | 59.0% |
营业利润率BHCOGN
| Q4 25 | 17.0% | -9.8% | ||
| Q3 25 | 23.1% | 15.2% | ||
| Q2 25 | 17.5% | 14.4% | ||
| Q1 25 | 12.2% | 6.7% | ||
| Q4 24 | 21.8% | 8.1% | ||
| Q3 24 | 12.7% | 13.1% | ||
| Q2 24 | 16.2% | 14.6% | ||
| Q1 24 | 13.1% | 14.5% |
净利率BHCOGN
| Q4 25 | -3.7% | -13.6% | ||
| Q3 25 | 6.7% | 10.0% | ||
| Q2 25 | 5.8% | 9.1% | ||
| Q1 25 | -2.6% | 5.8% | ||
| Q4 24 | 3.8% | 6.8% | ||
| Q3 24 | -3.4% | 22.7% | ||
| Q2 24 | 0.4% | 12.1% | ||
| Q1 24 | -3.0% | 12.4% |
每股收益（稀释后）BHCOGN
| Q4 25 | $-0.30 | $-0.78 | ||
| Q3 25 | $0.48 | $0.61 | ||
| Q2 25 | $0.40 | $0.56 | ||
| Q1 25 | $-0.16 | $0.33 | ||
| Q4 24 | $0.24 | $0.42 | ||
| Q3 24 | $-0.23 | $1.38 | ||
| Q2 24 | $0.03 | $0.75 | ||
| Q1 24 | $-0.17 | $0.78 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.3B | $574.0M |
| 总债务越低越好 | $20.8B | $8.6B |
| 股东权益账面价值 | $-554.0M | $752.0M |
| 总资产 | $26.4B | $12.9B |
| 负债/权益比越低杠杆越低 | — | 11.49× |
8季度趋势，按日历期对齐
现金及短期投资BHCOGN
| Q4 25 | $1.3B | $574.0M | ||
| Q3 25 | $1.3B | $672.0M | ||
| Q2 25 | $1.7B | $599.0M | ||
| Q1 25 | $1.1B | $547.0M | ||
| Q4 24 | $1.2B | $675.0M | ||
| Q3 24 | $719.0M | $763.0M | ||
| Q2 24 | $595.0M | $704.0M | ||
| Q1 24 | $733.0M | $575.0M |
总债务BHCOGN
| Q4 25 | $20.8B | $8.6B | ||
| Q3 25 | $21.0B | $8.8B | ||
| Q2 25 | $21.7B | $8.9B | ||
| Q1 25 | $21.5B | $9.0B | ||
| Q4 24 | $21.6B | $8.9B | ||
| Q3 24 | $21.5B | $8.7B | ||
| Q2 24 | $21.7B | $8.7B | ||
| Q1 24 | $22.1B | $8.7B |
股东权益BHCOGN
| Q4 25 | $-554.0M | $752.0M | ||
| Q3 25 | $-565.0M | $906.0M | ||
| Q2 25 | $-764.0M | $733.0M | ||
| Q1 25 | $-1.2B | $542.0M | ||
| Q4 24 | $-1.3B | $472.0M | ||
| Q3 24 | $-1.2B | $493.0M | ||
| Q2 24 | $-1.2B | $144.0M | ||
| Q1 24 | $-1.1B | $48.0M |
总资产BHCOGN
| Q4 25 | $26.4B | $12.9B | ||
| Q3 25 | $26.8B | $13.6B | ||
| Q2 25 | $27.3B | $13.5B | ||
| Q1 25 | $26.4B | $13.2B | ||
| Q4 24 | $26.5B | $13.1B | ||
| Q3 24 | $26.5B | $12.8B | ||
| Q2 24 | $26.5B | $12.2B | ||
| Q1 24 | $26.9B | $11.9B |
负债/权益比BHCOGN
| Q4 25 | — | 11.49× | ||
| Q3 25 | — | 9.74× | ||
| Q2 25 | — | 12.14× | ||
| Q1 25 | — | 16.52× | ||
| Q4 24 | — | 18.81× | ||
| Q3 24 | — | 17.75× | ||
| Q2 24 | — | 60.11× | ||
| Q1 24 | — | 181.54× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $495.0M | $141.0M |
| 自由现金流经营现金流 - 资本支出 | $403.0M | $96.0M |
| 自由现金流率自由现金流/营收 | 14.4% | 6.4% |
| 资本支出强度资本支出/营收 | 3.3% | 3.0% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $1.0B | $538.0M |
8季度趋势，按日历期对齐
经营现金流BHCOGN
| Q4 25 | $495.0M | $141.0M | ||
| Q3 25 | $405.0M | $264.0M | ||
| Q2 25 | $289.0M | $220.0M | ||
| Q1 25 | $211.0M | $75.0M | ||
| Q4 24 | $601.0M | $390.0M | ||
| Q3 24 | $405.0M | $141.0M | ||
| Q2 24 | $380.0M | $332.0M | ||
| Q1 24 | $211.0M | $76.0M |
自由现金流BHCOGN
| Q4 25 | $403.0M | $96.0M | ||
| Q3 25 | $314.0M | $218.0M | ||
| Q2 25 | $190.0M | $181.0M | ||
| Q1 25 | $96.0M | $43.0M | ||
| Q4 24 | $495.0M | $335.0M | ||
| Q3 24 | $334.0M | $99.0M | ||
| Q2 24 | $302.0M | $300.0M | ||
| Q1 24 | $129.0M | $30.0M |
自由现金流率BHCOGN
| Q4 25 | 14.4% | 6.4% | ||
| Q3 25 | 11.7% | 13.6% | ||
| Q2 25 | 7.5% | 11.4% | ||
| Q1 25 | 4.2% | 2.8% | ||
| Q4 24 | 19.3% | 21.0% | ||
| Q3 24 | 13.3% | 6.3% | ||
| Q2 24 | 12.6% | 18.7% | ||
| Q1 24 | 6.0% | 1.8% |
资本支出强度BHCOGN
| Q4 25 | 3.3% | 3.0% | ||
| Q3 25 | 3.4% | 2.9% | ||
| Q2 25 | 3.9% | 2.4% | ||
| Q1 25 | 5.1% | 2.1% | ||
| Q4 24 | 4.1% | 3.5% | ||
| Q3 24 | 2.8% | 2.7% | ||
| Q2 24 | 3.2% | 2.0% | ||
| Q1 24 | 3.8% | 2.8% |
现金转化率BHCOGN
| Q4 25 | — | — | ||
| Q3 25 | 2.26× | 1.65× | ||
| Q2 25 | 1.95× | 1.52× | ||
| Q1 25 | — | 0.86× | ||
| Q4 24 | 6.13× | 3.58× | ||
| Q3 24 | — | 0.39× | ||
| Q2 24 | 38.00× | 1.70× | ||
| Q1 24 | — | 0.38× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BHC
| Bausch Lomb | $1.4B | 50% |
| Salix Segment | $693.0M | 25% |
| International Rx | $306.0M | 11% |
| Diversified Segment | $255.0M | 9% |
| Solta Medical Segment | $137.0M | 5% |
OGN
暂无分部数据
